Jasper Therapeutics (JSPR) Stock Forecast & Price Target

$3.51 -0.04 (-1.13%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$3.42 -0.09 (-2.71%)

As of 07/11/2025 07:58 PM Eastern

Jasper Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 10 Analyst Ratings

Sell
0

Hold
4

Buy
6

Based on 10 Wall Street analysts who have issued ratings for Jasper Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 10 analysts, 4 have given a hold rating, and 6 have given a buy rating for JSPR.

Consensus Price Target

$29.75
747.58% Upside

According to the 10 analysts' twelve-month price targets for Jasper Therapeutics, the average price target is $29.75. The highest price target for JSPR is $65.00, while the lowest price target for JSPR is $5.00. The average price target represents a forecasted upside of 747.58% from the current price of $3.51.

Get the Latest News and Ratings for JSPR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Jasper Therapeutics and its competitors.

JSPR Analyst Ratings Over Time

Type	Current Forecast 7/14/24 to 7/14/25	1 Month Ago 6/14/24 to 6/14/25	3 Months Ago 4/15/24 to 4/15/25	1 Year Ago 7/15/23 to 7/14/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	6 Buy rating(s)	10 Buy rating(s)	9 Buy rating(s)	11 Buy rating(s)
Hold	4 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$29.75	$62.22	$62.50	$69.56
Forecasted Upside	747.58% Upside	1,015.09% Upside	1,377.54% Upside	264.17% Upside
Consensus Rating	Moderate Buy	Buy	Buy	Buy

JSPR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

JSPR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Jasper Therapeutics Stock vs. The Competition

Type	Jasper Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.60	2.80	2.54
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	747.58% Upside	8,634.01% Upside	10.52% Upside
News Sentiment Rating	Neutral News See Recent JSPR News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
7/8/2025	Royal Bank Of Canada 3 of 5 stars	G. Renza Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Sector Perform	$5.00	+64.47%
7/8/2025	JMP Securities 2 of 5 stars	Silvan Tuerkcan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Market Outperform ➝ Market Outperform	$70.00 ➝ $12.00	+276.17%
7/8/2025	Evercore ISI 2 of 5 stars	Gavin Clark-Gartner Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$50.00 ➝ $20.00	+557.89%
7/8/2025	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Kostas Biliouris Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
7/7/2025	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Emily Bodnar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$40.00 ➝ $20.00	+557.89%
7/7/2025	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Justin Zelin Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$64.00 ➝ $20.00	+557.89%
7/7/2025	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Pete Stavropoulos Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral
7/7/2025	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Matt Phipps Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
5/15/2025	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Jay Olson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$80.00 ➝ $65.00	+1,232.24%
5/13/2025	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Huynh Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$38.00 ➝ $33.00	+587.50%
Get the Latest News and Ratings for JSPR and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Jasper Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
6/27/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$86.00	+309.91%
3/18/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform
8/14/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$40.00	+200.75%
8/11/2023	Capital One Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Chiang Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$70.00	+396.45%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 01:39 AM ET.

JSPR Forecast - Frequently Asked Questions

: According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Jasper Therapeutics is $29.75, with a high forecast of $65.00 and a low forecast of $5.00.
: 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Jasper Therapeutics in the last year. There are currently 4 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" JSPR shares.
: According to analysts, Jasper Therapeutics's stock has a predicted upside of 747.58% based on their 12-month stock forecasts.
: Over the previous 90 days, Jasper Therapeutics's stock had 2 downgrades by analysts.
: Jasper Therapeutics has been rated by research analysts at BMO Capital Markets, BTIG Research, Cantor Fitzgerald, Evercore ISI, HC Wainwright, JMP Securities, Oppenheimer, Royal Bank Of Canada, UBS Group, and William Blair in the past 90 days.
: Analysts like Jasper Therapeutics less than other "medical" companies. The consensus rating score for Jasper Therapeutics is 2.60 while the average consensus rating score for "medical" companies is 2.80. Learn more on how JSPR compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:JSPR) was last updated on 7/14/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Jasper Therapeutics (JSPR) Stock Forecast & Price Target